In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.

Patients with rheumatoid arthritis (RA) undergoing standard-of-care treatment frequently have persisting pain.

US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...

Imuldosa is a biosimilar to Stelara, a blockbuster drug developed by Janssen Biotech for the treatment of patients with ...

Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...

Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...

Arthritis is a chronic inflammatory condition that affects the joints, causing swelling, pain, and stiffness. It is one of ...

Treatment for arthritis is mainly focused on symptom management and slowing the progression of the disease, says Dr Vishal ...

Lifestyle changes become critical components of arthritis management. An appropriate diet, low-impact exercise, and ...

Arthritis, often thought to be an ailment of the elderly, is an autoimmune disease prevalent across all ages, particularly in ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.